Leerink Swann Trims Regeneron Pharmaceuticals (REGN) Target Price to $502.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective lowered by equities researchers at Leerink Swann from $568.00 to $502.00 in a research note issued to investors on Friday. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. Leerink Swann’s target price suggests a potential upside of 49.24% from the company’s current price.

A number of other equities research analysts have also recently commented on REGN. Canaccord Genuity restated a “buy” rating on shares of Regeneron Pharmaceuticals in a report on Monday, October 16th. JPMorgan Chase & Co. reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Monday, October 16th. Barclays cut shares of Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and reduced their price objective for the company from $450.00 to $395.00 in a report on Friday, October 20th. Guggenheim reiterated a “buy” rating and set a $540.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, October 23rd. Finally, Robert W. Baird upgraded shares of Regeneron Pharmaceuticals from an “underperform” rating to a “neutral” rating in a report on Friday, November 3rd. Four research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eleven have given a buy rating to the company’s stock. Regeneron Pharmaceuticals has an average rating of “Hold” and an average price target of $463.19.

Regeneron Pharmaceuticals (NASDAQ REGN) traded up $13.76 during trading hours on Friday, reaching $336.38. 2,086,830 shares of the company’s stock were exchanged, compared to its average volume of 950,286. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.63 and a quick ratio of 3.07. The firm has a market capitalization of $36,140.00, a PE ratio of 32.59, a price-to-earnings-growth ratio of 1.26 and a beta of 1.47. Regeneron Pharmaceuticals has a 1-year low of $314.99 and a 1-year high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 EPS for the quarter, topping analysts’ consensus estimates of $4.18 by $1.05. The business had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.50 billion. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The business’s quarterly revenue was up 28.9% on a year-over-year basis. During the same period last year, the company posted $3.04 earnings per share. research analysts forecast that Regeneron Pharmaceuticals will post 13.55 EPS for the current year.

A number of hedge funds have recently made changes to their positions in REGN. Steward Partners Investment Advisory LLC raised its position in Regeneron Pharmaceuticals by 495.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 369 shares of the biopharmaceutical company’s stock worth $138,000 after acquiring an additional 307 shares during the period. Advisory Services Network LLC increased its stake in shares of Regeneron Pharmaceuticals by 147.0% in the fourth quarter. Advisory Services Network LLC now owns 447 shares of the biopharmaceutical company’s stock worth $168,000 after purchasing an additional 266 shares in the last quarter. Vident Investment Advisory LLC purchased a new position in shares of Regeneron Pharmaceuticals in the third quarter worth about $200,000. Virtu KCG Holdings LLC purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter worth about $206,000. Finally, AE Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $206,000. 65.69% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Leerink Swann Trims Regeneron Pharmaceuticals (REGN) Target Price to $502.00” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2018/02/09/leerink-swann-trims-regeneron-pharmaceuticals-regn-target-price-to-502-00.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply